Clinical Trials | April 04, 2024
Evonik unveils latest global trial results MetAMINO
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
This acquisition enables MTD to open new, strategic markets
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
An accomplished R&D leader and champion of the application of AI to drug discovery
This product has sales of about US$ 20 million in Europe
Subscribe To Our Newsletter & Stay Updated
